Brammer Bio, a best-in-class viral vector contract development and manufacturing organization (CDMO), has announced that a three-year, $200 million investment program is on track to establish over 30 suites for clinical and commercial viral vector supply for a broad pipeline of advanced gene therapies and gene-modified cell therapies.
“Brammer’s vision is to enable innovators to bring these advanced medicines to patients. We are committed to continuing our investment in our world-class team and facilities for manufacturing gene therapies,” said Brammer Bio President and CEO Mark Bamforth. “Brammer is uniquely positioned to support the dramatic growth of the gene and cell therapy sector through the application of our team’s deep technical and operational experience in developing and manufacturing gene therapies and gene-modified cell therapies.”
At its Alachua, Florida facilities, Brammer is building on a 12+ year track record of supplying first-in-human clinical materials by expanding its process and analytical development laboratories and quality control laboratories by the end of 2018. This expansion follows a doubling of its clinical capacity in Alachua in 2017. The site incorporates equipment and design concepts that are setting the standard for process and analytical development for clinical trials and ultimately commercial scale manufacturing. More than 220 Alachua-based skilled staff occupy a three-building campus totaling 80,000 square feet.
Additional expansions and renovations in the company’s commercial facilities in Cambridge and Lexington, Massachusetts have also been announced.
By mid-2019, Brammer will have 700 employees focused solely on providing viral vector products to multiple clients, an increase from its current staff of 500. The company has more than doubled its staff over the past year.
